Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

Showing 26 to 34 of 34

TitleReference numberPublishedLast updated
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357

Results per page

  1. 10
  2. 25
  3. 50
  4. All